Immutep’s Promising Trial Results in Cancer Therapy

Immutep Ltd (AU:IMM) has released an update.

Immutep Ltd has revealed promising results from its Phase IIb trial of eftilagimod alpha combined with pembrolizumab in patients with head and neck cancer, showing significant improvements in overall survival and response rates. The combination therapy achieved a 12-month overall survival rate of 67% and increased complete response rates, marking a potential breakthrough for patients with limited treatment options. These findings highlight the potential of Immutep’s immunotherapy to enhance outcomes for a challenging patient population.

For further insights into AU:IMM stock, check out TipRanks’ Stock Analysis page.